This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Avid Bioservices (CDMO) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 33.33% and 7.92%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Evogene (EVGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of -16.67% and 83.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Kamada (KMDA) Q2 Earnings Beat Estimates
by Zacks Equity Research
Kamada (KMDA) delivered earnings and revenue surprises of 450% and 1.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0% and 26.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 80% and 12.53%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Avid Bioservices (CDMO) closed at $20.24 in the latest trading session, marking a -0.3% move from the prior day.
Arcus Biosciences, Inc. (RCUS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 428.32% and 3,898.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Avid (CDMO) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
Avid Bioservices (CDMO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Avid Bioservices (CDMO) closed the most recent trading day at $21.25, moving -1.16% from the previous trading session.
Avid Bioservices (CDMO) Stock Moves -1.6%: What You Should Know
by Zacks Equity Research
In the latest trading session, Avid Bioservices (CDMO) closed at $21.54, marking a -1.6% move from the previous day.
Avid Bioservices (CDMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Avid Bioservices (CDMO) closed at $18.97 in the latest trading session, marking a +0.53% move from the prior day.
Avid Bioservices (CDMO) Stock Moves -1.67%: What You Should Know
by Zacks Equity Research
In the latest trading session, Avid Bioservices (CDMO) closed at $18.20, marking a -1.67% move from the previous day.
Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Gilead Sciences, Regeneron and Avid Bioservices
Follow The Leader: 3 Biopharma Stocks Displaying Relative Strength
by Bryan Hayes
3 Biopharma Stocks Displaying Relative Strength Heading Into 2022
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon.
Avid Bioservices (CDMO) Loses 24.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Avid Bioservices (CDMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Avid Bioservices (CDMO) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 400% and 4.44%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Q4 Earnings Lag Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of -2.67% and 1.52%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices (CDMO) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata (RETA) Confirms Omaveloxolone NDA Filing in Q1 2022
by Zacks Equity Research
Reata (RETA) confirms submission of an NDA seeking approval for omaveloxolone to the FDA in the first quarter of 2022, following the completion of its pre-NDA meeting with the FDA.
Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
by Zacks Equity Research
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?
by Zacks Equity Research
Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.